Evaluating New Zealanders’ Values for Drug Coverage Decision Making: Trade-Offs between Treatments for Rare and Common Conditions

RT @PECjournal: Study suggests NZ'ers do not value disease rarity on its own when prioritising funding decisions @dean_sop @OtagoPharmacy @…

'NZers ultimately value drug-related factors (e.g. QoL & efficacy) & disease-related factors (e.g. severity of disease & equity) the most in the drug funding decision-making process.' - L Yamoah @NickDragojlovic @Inquisitnz @ldlynd @dean_sop…

RT @PECjournal: Study suggests NZ'ers do not value disease rarity on its own when prioritising funding decisions @dean_sop @OtagoPharmacy @…

Study suggests NZ'ers do not value disease rarity on its own when prioritising funding decisions @dean_sop @OtagoPharmacy @PHARMACnz https://t.co/dB8m9EdjiH